Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535854 · ClinicalTrials.gov registry record · NA
Prevail Global Study
A NA study of Coronary Artery Disease, sponsored by Medtronic Vascular.
- Recruiting
- Registry status
- NA
- Development phase
- 1,205
- Enrollment target
- 20
- Study locations
NCT06535854: Recruiting NA study of Coronary Artery Disease, sponsored by Medtronic Vascular.
NCT06535854 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Medtronic Vascular. The registered enrollment target is 1,205 participants, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06535854, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Medtronic Vascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,205 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
Primary Outcome
The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority
Conditions Studied
Interventions
- DEVICE Prevail DCB
- DEVICE Agent DCB
Study Locations (20)
Florida
- BayCare Health System - Clearwater
- North Florida Regional Medical Center - Gainesville
- University of Miami Hospital - Miami
Alabama
- The University of Alabama at Birmingham - Birmingham
- Huntsville Hospital - Huntsville
Georgia
- Emory University Hospital Midtown - Atlanta
- Piedmont Atlanta Hospital - Atlanta
Illinois
- Advocate Illinois Masonic Medical Center - Chicago
- Midwest Cardiovascular Institute - Naperville
Kansas
- Kansas City Heart Rhythm Institute (Midwest Heart and Vascular Specialist) - Overland Park
- Ascension Via Christi Saint Francis - Wichita
Michigan
- Corewell Health - Grand Rapids
- Saint Joseph Mercy Ann Arbor - Ypsilanti
Arizona
- Carondelet Saint Marys - Tucson
Arkansas
- John L McClellan Memorial Veterans Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,205 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2031-02 |
| Phase | NA |
What NCT06535854 shows while recruiting
NCT06535854 is an interventional study that assigns participants to a tested intervention. Its 1,205 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Prevail DCB is the first listed.
NCT06535854 names 20 study sites across 13 states, led by Florida, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT06535854 about?
NCT06535854 is a clinical study titled "Prevail Global Study". The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
What is the current status of trial NCT06535854?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,205 participants. The study started on 2025-02-24. Estimated completion is 2031-02.
What conditions does trial NCT06535854 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT06535854?
The interventions under investigation include: Prevail DCB (DEVICE), Agent DCB (DEVICE).
Who is sponsoring clinical trial NCT06535854?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06535854 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06535854's enrollment target sits among peer trials
1,205 42nd of 219 higher than 178 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT07038785 · 1,204 participants
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI